Celgene Corporation http://www.alacrastore.com/company-snapshot/Celgene_Corporation-1003217 Saturday, July 26, 2008 1:39:55 PM 1003217 Celgene Corporation en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/B1902725ccbn/B1902725norm...Quarterly revenues and earnings climbed to new highs while Co. continues to drive commercial expansion and pipeline advancement in all markets. ... 7/24/2008 10:14:59 PMCelgene Corp.106.0000EditedQ2 2008 Celgene Corp. Earnings Conference Call SummaryCELG9:00am ETBriefB1902725Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1902725ccbn/T1902725norm...Good morning. My name is Stacey, and I will be your conference operator today. At this time I'd like to welcome everyone to the Celgene Quarterly Conference Call. As a reminder today's call is being recorded. I would now like to turn the call over to David Gryska, Chief Financial Officer. Please go ahead, sir. ... 7/24/2008 11:04:00 AMCelgene Corp.106.0000FinalQ2 2008 Celgene Corp. Earnings Conference Call TranscriptCELG9:00am ETTranscriptT1902725Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1856915ccbn/T1856915norm... - Jefferies & Company - AnalystOur next presenting company is Celgene. Celgene is the fourth-largest biotech company, and it's growing. So we are happy to have David Gryska, who is the CFO of Celgene. He's actually presenting at Jefferies conference three years in a row. So we're very happy to have him today as well. ... 6/25/2008 11:04:00 PMCelgene Corp.54.0000FinalCelgene Corp. at Jefferies & Co. Annual Healthcare Conference TranscriptCELG9:30am ETTranscriptT1856915Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1852457ccbn/T1852457norm...Good morning. I think we will go ahead and get started this morning. Our next presentation is from Celgene. This is ticker CELG and it is stock that we rate alpha form on a basis of the Company's growth outlook and growth profile which we think is among the best if not the best in large cap health care. The presenter today is David Gryska, Chief Financial Officer. I would encourage all of you to see full disclosures for me and for our firm on www.williamblair.com. With that I'll turn the podium over to David and I'll also let you know that the breakout for this session is downstairs in the lounge. David. ... 6/19/2008 6:04:00 PMCelgene Corp.54.0000FinalCelgene Corp. at William Blair & Company Growth Stock Conference TranscriptCELG7:30am CTTranscriptT1852457Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/HUG-0001-25932924newstex/HUG-0001-25932924xml Jun. ##, #### (Hugin AS delivered by Newstex) -- Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. -----------------------------------------------------------------...0400000004002000040020010400200604016000040160311300000013010000130100050700000007001000070010040701400007014008070140120200000002002000020020086/12/2008 5:19:54 AM180000001801800019000000190020001900200719002018Hugin ASHUG-0001-25932924BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLECELGENE CORPSPECTRUM PHARMACEUTICALS INCBMYBMY PRCELGSPPINewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1861266ccbn/T1861266norm... - Goldman Sachs - Analyst and Moderator We will continue with the discussion this morning with Celgene; and we are delighted to have Dr. Sol Barer, who is the CEO of the Company, with us this morning. We were speaking last night and Sol's goal is to build Celgene into the premier company for hematology/oncology. And he's a Renaissance man, I guess. He was studying law for a while right? And you -- he was just talking about energy prices and he was involved in energy before as well. So we're happy that you have (inaudible) time to come and speak to us. Please. ... 6/11/2008 5:05:00 PMCelgene Corp.54.0000FinalCelgene Corp. at Goldman Sachs Healthcare Conference TranscriptCELG10:00am PTTranscriptT1861266Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1856912ccbn/T1856912norm...Good morning and, once again, welcome to the seventh annual Needham & Company Biotech and Medical Technology Conference. Our next question station is going to be by Celgene and we're very pleased to have David Gryska, the Chief Financial Officer of Celgene, here to present for us. ... 6/11/2008 1:06:00 PMCelgene Corp.54.0000FinalCelgene Corp. at Needham & Company Biotechnology and Medical Technology Conference TranscriptCELG10:00am ETTranscriptT1856912Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1856906ccbn/T1856906norm... - Friedman, Billings, Ramsey - AnalystOkay. It's ##:## so I think we'll go ahead and get started with the next presentation this morning, and that is Celgene. And we're very fortunate to have with us today Perry Karsen, who is Senior Vice President for Business Development. And it's a good story so I'll go ahead and turn it over to Perry so we can get started and then we'll have hopefully ## minutes for questions at the end. Thanks. Thank you, Perry. ... 5/28/2008 9:04:00 PMCelgene Corp.54.0000FinalCelgene Corp. at FBR Capital Markets Annual Spring Investor Conference TranscriptCELG11:15am ETTranscriptT1856906Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1853788ccbn/T1853788norm...The audio available for this event is muffled and difficult to understand, the transcript was prepared using this audio and is best product.... 5/22/2008 10:05:00 PMCelgene Corp.54.0000FinalCelgene Corp. at NASDAQ Investor Program TranscriptCELG8:30am UKTTranscriptT1853788Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1846188ccbn/T1846188norm...Sorry. Thanks very much for hanging in to the end of the conference for the Celgene presentation and thanks to Citi and (inaudible) for including us. It has already been a great day for me, had an opportunity to do a lot of one-on-one us and really get into some depth of issues both in the short-term and medium-term about Celgene and look forward to that in the breakout session also. So thanks for joining us. The presentation does include forward-looking statements that involve risk. Actual results may or may not be as we discuss here today. We have started our presentations for many years, almost a decade now with this same slide. I think it's important for everybody to understand how important it is to us because it is both the value proposition for our Company and it really is the unifying positioning of all of the people in our Company who ae committed to making a difference in patients' lives around the world. And as a value proposition for a shareholder it is also critically important... 5/22/2008 5:05:00 PMCelgene Corp.54.0000PreliminaryCelgene Corp. at Citigroup Healthcare Conference TranscriptCELG3:30pm ETTranscriptT1846188Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1856905ccbn/T1856905norm... - JMP Securities - AnalystMichael, I'm going to go for it here, give it a start. Well, good morning. We are making progress in -- with our program this morning, and it's my pleasure to introduce the largest market cap company that we have presenting in the biotech space, healthcare space at our conference this year. Actually has been the largest market cap company for the last couple of years. And interestingly, although many of our stocks continue to expand their market cap, this one is beating them all. And the reason is because this is the most, I think, compelling growth story in the large cap biotech space now. Celgene is a company that has not only a significant growth product that was recently approved in the last ## months or so in REVLIMID, but it is the leading -- the leader in the sale of hematology products and has recently merged or acquired a company called Pharmion and further bolstered its pipeline and product portfolio. With me this morning is Mr. Perry Carson who is... 5/21/2008 6:04:00 PMCelgene Corp.54.0000FinalCelgene Corp. at JMP Securities Research Conference TranscriptCELG10:30am PTTranscriptT1856905Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1847450ccbn/T1847450norm... - Banc of America Securities - AnalystI'm Katherine Kim, biotech analyst at Banc of America, and just wanted to thank everyone for coming today and also for lasting this long. We're almost to the end, and I'm now pleased to introduce to you next speaker. He's the Chief Operating Officer of Celgene Corporation, Mr. Bob Hugin. ... 5/15/2008 5:06:00 PMCelgene Corp.54.0000FinalCelgene Corp. at Bank of America Securities Health Care Conference TranscriptCELG4:40pm PTTranscriptT1847450Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/HUG-0001-25286454newstex/HUG-0001-25286454xml May ##, #### (Hugin AS delivered by Newstex) -- Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------...040000000400200004002001040020060401600004016048040160010401601804016005040160031300000013010000130100055/15/2008 3:20:34 AM1800000018008000180040001801600018020000190000001900200019002018Hugin ASHUG-0001-25286454CELGENE CORPCELGNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1832759ccbn/T1832759norm...Well, good morning. I think we're going to go ahead and get started for our next session. Thanks, everybody, for being here. My name is Chris Raymond. I am Baird's senior biotechnology analyst. I'm very pleased to announce our next presenter here, which is Celgene Corporation, a large cap commercial biopharmaceutical company, primarily focused on the development of orally available small molecule therapeutics for the treatment of cancer and inflammatory diseases, primarily. The Company's major marketed products include REVLIMID, THALOMID and just recently acquired VIDAZA. THALOMID is currently the dominant therapy in front line multiple myeloma in the United States, while REVLIMID, with its primary indications in MDS, which is myelodysplastic syndrome, and also in relapsed/refractory multiple myeloma, is seeing very rapid uptake. With us today are David Gryska, Senior Vice President and Chief Financial Officer, and also Brian Gill, Director of Investor Relations. Before we begin, I'd like... 5/13/2008 7:06:00 PMCelgene Corp.54.0000FinalCelgene Corp. at Robert W. Baird & Co., Inc. Growth Stock Conference TranscriptCELG11:50am CTTranscriptT1832759Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/CCN-0001-25193846newstex/CCN-0001-25193846xml MONTREAL, QUEBEC, May ##, #### (Marketwire delivered by Newstex) -- MethylGene Inc. (TSX:MYG) today announced operational and financial results for the first quarter ended March ##, ####. Highlights - Formed a worldwide research collaboration...070000000700500004000000040020000400200604016000040160470401600104016018040090000400900207014000070140080701401207001000070010041300000013010000130100055/12/2008 8:18:23 AM18000000180120001800400018010000190000001900200019002012Marketwire CanadaCCN-0001-25193846CELGENE CORPMETHYLGENE INCCELGMYGNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-25193553newstex/MW-0001-25193553xml MONTREAL, QUEBEC, May ##, #### (Marketwire delivered by Newstex) -- MethylGene Inc. (TSX: MYG) today announced operational and financial results for the first quarter ended March ##, ####. Highlights - Formed a worldwide research collaboration...070000000700500004000000040020000400200604016000040160470401600104016018040090000400900207014000070140080701401207001000070010041300000013010000130100055/12/2008 8:18:23 AM18000000180120001800400018010000190000001900200019002012MarketwireMW-0001-25193553CELGENE CORPMETHYLGENE INCCELGMYGNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1839882ccbn/B1839882norm...Increase was driven by growing revenue streams including record quarterly product sales from Revlimid and sales of Thalomid. ... 5/8/2008 12:05:00 PMCelgene Corp.54.0000EditedQ1 2008 Celgene Corp. Earnings Conference Call SummaryCELG9:00am ETBriefB1839882Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1839882ccbn/T1839882norm...Good morning. My name is Candace, I will be your conference operator today. At this time I would like to welcome everyone to the Celgene first quarter conference call. At this time I would like to turn the conference over to Mr. David Gryska, Chief Financial Officer. Please go ahead, sir. ... 5/8/2008 11:05:00 AMCelgene Corp.54.0000FinalQ1 2008 Celgene Corp. Earnings Conference Call TranscriptCELG9:00am ETTranscriptT1839882Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-25113397newstex/BW-0001-25113397xml SUMMIT, N.J., May #, #### (Business Wire) -- #### First Quarter Financial Results Year-Over-Year -- Non-GAAP Total Revenues Increased ## Percent to $###.# Million; GAAP Total Revenues $###.# Million -- REVLIMID(R)...07000000070050000701300009000000090150000400000004016000040160480401601804016003040160050401600104002000040020060701400007014008070010000700100407003000070030015/8/2008 8:17:28 AM18000000180040001800800018016000180200001900000019001000190020001900200719002018Business WireBW-0001-25113397CELGENE CORPSOL J BARERCELGNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1816789ccbn/T1816789norm... - Morgan Stanley - AnalystGood afternoon, thanks for joining us. This is Sapna, biotechnology analyst at Morgan Stanley, joined by Bob Hugin from Celgene. We want to make this really interactive, so please ask as many questions and make it is useful as it can be. I will just kick it get off by saying that we have disclosures which are posted on our personal holdings and Morgan Stanley holdings on the Morgan Stanley public website at www.morganstanley.com. ... 5/2/2008 1:05:00 PMCelgene Corp.54.0000FinalCelgene Corp. at Morgan Stanley 2008 Global Healthcare Unplugged Conference TranscriptCELG3:40pm ETTranscriptT1816789Credit & Investment ResearchThomson Street Events